{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:22:59Z","timestamp":1791559379913,"version":"4.3.4"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,16]]},"DOI":"10.7759\/cureus.114587","type":"journal-article","created":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T08:08:21Z","timestamp":1786867701000},"source":"Crossref","is-referenced-by-count":1,"title":["Spironolactone-Induced Bilateral Gynecomastia in a Patient With Comorbid Conditions"],"prefix":"10.7759","author":[{"given":"Shruti Vihang","family":"Brahmbhatt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deshna","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecl.2007.03.013","article-title":"Gynecomastia","volume":"36","author":"Narula HS","year":"2007","unstructured":"Narula HS, Carlson HE. Gynecomastia. Endocrinol Metab Clin North Am. 2007, 36:497-519. 10.1016\/j.ecl.2007.03.013","journal-title":"Endocrinol Metab Clin North Am"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp070677","article-title":"Gynecomastia","volume":"357","author":"Braunstein GD","year":"2007","unstructured":"Braunstein GD. Gynecomastia. N Engl J Med. 2007, 357:1229-37. 10.1056\/NEJMcp070677","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2012.712109","article-title":"Drug-induced gynecomastia: an evidence-based review","volume":"11","author":"Deepinder F","year":"2012","unstructured":"Deepinder F, Braunstein GD. Drug-induced gynecomastia: an evidence-based review. Expert Opin Drug Saf. 2012, 11:779-95. 10.1517\/14740338.2012.712109","journal-title":"Expert Opin Drug Saf"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1590\/s1516-31802012000300009","article-title":"Gynecomastia: physiopathology, evaluation and treatment","volume":"130","author":"Barros AC","year":"2012","unstructured":"Barros AC, Sampaio Mde C. Gynecomastia: physiopathology, evaluation and treatment. Sao Paulo Med J. 2012, 130:187-97. 10.1590\/s1516-31802012000300009","journal-title":"Sao Paulo Med J"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-87-4-398","article-title":"Pathophysiology of spironolactone-induced gynecomastia","volume":"87","author":"Rose LI","year":"1977","unstructured":"Rose LI, Underwood RH, Newmark SR, Kisch ES, Williams GH. Pathophysiology of spironolactone-induced gynecomastia. Ann Intern Med. 1977, 87:398-403. 10.7326\/0003-4819-87-4-398","journal-title":"Ann Intern Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jash.2010.10.001","article-title":"The effect of low-dose spironolactone on resistant hypertension","volume":"4","author":"Engbaek M","year":"2010","unstructured":"Engbaek M, Hjerrild M, Hallas J, Jacobsen IA. The effect of low-dose spironolactone on resistant hypertension. J Am Soc Hypertens. 2010, 4:290-4. 10.1016\/j.jash.2010.10.001","journal-title":"J Am Soc Hypertens"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.4065\/84.11.1010","article-title":"Gynecomastia: pathophysiology, evaluation, and management","volume":"84","author":"Johnson RE","year":"2009","unstructured":"Johnson RE, Murad MH. Gynecomastia: pathophysiology, evaluation, and management. Mayo Clin Proc. 2009, 84:1010-5. 10.4065\/84.11.1010","journal-title":"Mayo Clin Proc"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/49.9.2229","article-title":"Preventability and severity assessment in reporting adverse drug reactions","volume":"49","author":"Hartwig SC","year":"1992","unstructured":"Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting adverse drug reactions. Am J Hosp Pharm. 1992, 49:2229-32. 10.1093\/ajhp\/49.9.2229","journal-title":"Am J Hosp Pharm"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1138","article-title":"Drug-induced gynecomastia","volume":"32","author":"Bowman JD","year":"2012","unstructured":"Bowman JD, Kim H, Bustamante JJ. Drug-induced gynecomastia. Pharmacotherapy. 2012, 32:1123-40. 10.1002\/phar.1138","journal-title":"Pharmacotherapy"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo CA","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, et al.. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981, 30:239-45. 10.1038\/clpt.1981.154","journal-title":"Clin Pharmacol Ther"},{"key":"ref11","article-title":"Focusing on the preventability of adverse drug reactions","volume":"27","author":"Schumock GT","year":"1992","unstructured":"Schumock GT, Thornton JP. Focusing on the preventability of adverse drug reactions. Hosp Pharm. 1992, 27:538.","journal-title":"Hosp Pharm"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/cpt1978244465","article-title":"Gynecomastia induced in normal males by spironolactone","volume":"24","author":"Huffman DH","year":"1978","unstructured":"Huffman DH, Kampmann JP, Hignite CE, Azarnoff DL. Gynecomastia induced in normal males by spironolactone. Clin Pharmacol Ther. 1978, 24:465-73. 10.1002\/cpt1978244465","journal-title":"Clin Pharmacol Ther"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMicm2510742","article-title":"Spironolactone-induced gynecomastia","volume":"393","author":"Celik AI","year":"2025","unstructured":"Celik AI, Bezgin T. Spironolactone-induced gynecomastia. N Engl J Med. 2025, 393:2151. 10.1056\/NEJMicm2510742","journal-title":"N Engl J Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/495974-spironolactone-induced-bilateral-gynecomastia-in-a-patient-with-comorbid-conditions","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T08:08:22Z","timestamp":1786867702000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/495974-spironolactone-induced-bilateral-gynecomastia-in-a-patient-with-comorbid-conditions"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,16]]},"references-count":13,"URL":"https:\/\/doi.org\/10.7759\/cureus.114587","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,16]]}}}